190 related articles for article (PubMed ID: 26941130)
41. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
[TBL] [Abstract][Full Text] [Related]
43. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.
Karadag O; Farisogullari B; Yagiz B; Erden A; Ademoglu Z; Kimyon G; Bilge NS; Icacan OC; Kilic L; Coskun BN; Ersozlu ED; Kucuksahin O; Mercan R; Koca SS; Gonullu E; Cinar M; Akar S; Emmungil H; Kasifoglu T; Bes C; Omma A; Pehlivan Y; Kiraz S; Ertenli I; Dalkilic E; Kalyoncu U
Clin Exp Rheumatol; 2024 Jan; 42(1):130-137. PubMed ID: 37650346
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
Addimanda O; Possemato N; Macchioni P; Salvarani C
Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
46. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
48. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.
Hoshi D; Nakajima A; Shidara K; Seto Y; Tanaka E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2013 Nov; 23(6):1205-10. PubMed ID: 23456321
[TBL] [Abstract][Full Text] [Related]
49. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
50. Shorter disease duration is important for tocilizumab to achieve Boolean remission.
Kawasaki Y; Hashimoto T; Okano T; Sakai Y; Yamane T; Shiozawa K; Shiozawa S; Hashiramoto A
Mod Rheumatol; 2013 Nov; 23(6):1192-7. PubMed ID: 23380997
[TBL] [Abstract][Full Text] [Related]
51. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
Kobayashi Y; Kobayashi H; Giles JT; Hirano M; Nakajima Y; Takei M
Int J Rheum Dis; 2016 Nov; 19(11):1169-1174. PubMed ID: 26480957
[TBL] [Abstract][Full Text] [Related]
52. Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
Álvaro-Gracia JM; Fernández-Nebro A; García-López A; Guzmán M; Blanco FJ; Navarro FJ; Bustabad S; Armendáriz Y; Román-Ivorra JA;
Reumatol Clin; 2014; 10(2):94-100. PubMed ID: 24099961
[TBL] [Abstract][Full Text] [Related]
53. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
Gossec L; Steinberg G; Rouanet S; Combe B
Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
[TBL] [Abstract][Full Text] [Related]
54. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?
Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F
Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685
[TBL] [Abstract][Full Text] [Related]
55. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.
Pers YM; Fortunet C; Constant E; Lambert J; Godfrin-Valnet M; De Jong A; Mercier G; Pallot Prades B; Wendling D; Gaudin P; Jorgensen C; Marotte H; Maillefert JF
Rheumatology (Oxford); 2014 Jan; 53(1):76-84. PubMed ID: 24056521
[TBL] [Abstract][Full Text] [Related]
56. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
Hirabayashi Y; Munakata Y; Miyata M; Urata Y; Saito K; Okuno H; Yoshida M; Kodera T; Watanabe R; Miyamoto S; Ishii T; Nakazawa S; Takemori H; Ando T; Kanno T; Komagamine M; Kato I; Takahashi Y; Komatsuda A; Endo K; Murai C; Takakubo Y; Miura T; Sato Y; Ichikawa K; Konta T; Chiba N; Muryoi T; Kobayashi H; Fujii H; Sekiguchi Y; Hatakeyama A; Ogura K; Sakuraba H; Asano T; Kanazawa H; Suzuki E; Takasaki S; Asakura K; Sugisaki K; Suzuki Y; Takagi M; Nakayama T; Watanabe H; Miura K; Mori Y;
Mod Rheumatol; 2016 Nov; 26(6):828-835. PubMed ID: 26934116
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis.
Pers YM; Schaub R; Constant E; Lambert J; Godfrin-Valnet M; Fortunet C; Bourichi W; Prades BP; Wendling D; Gaudin P; Jorgensen C; Maillefert JF; Marotte H
Joint Bone Spine; 2015 Jan; 82(1):25-30. PubMed ID: 25241333
[TBL] [Abstract][Full Text] [Related]
58. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
59. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
[TBL] [Abstract][Full Text] [Related]
60. Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.
Fechtenbaum M; Lasselin-Boyard P; Salomon S; Jelin G; Millot F; Grados F; Fardellone P; Goëb V
Pharmacology; 2016; 98(1-2):73-8. PubMed ID: 27115145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
